These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 9376453

  • 1. Major depressive subtypes and treatment response.
    Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF.
    Biol Psychiatry; 1997 Oct 01; 42(7):568-76. PubMed ID: 9376453
    [Abstract] [Full Text] [Related]

  • 2. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U, Onder E.
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec 01; 253(6):307-12. PubMed ID: 14714120
    [Abstract] [Full Text] [Related]

  • 3. Predictors of an acute antidepressant response to fluoxetine and sertraline.
    Flament MF, Lane RM, Zhu R, Ying Z.
    Int Clin Psychopharmacol; 1999 Sep 01; 14(5):259-75. PubMed ID: 10529069
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J.
    Int Clin Psychopharmacol; 2008 Sep 01; 23(5):269-75. PubMed ID: 18703936
    [Abstract] [Full Text] [Related]

  • 5. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
    Marchesi C, Ceccherininelli A, Rossi A, Maggini C.
    Pharmacopsychiatry; 1998 Nov 01; 31(6):216-21. PubMed ID: 9930635
    [Abstract] [Full Text] [Related]

  • 6. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
    Howland RH, Rush AJ, Wisniewski SR, Trivedi MH, Warden D, Fava M, Davis LL, Balasubramani GK, McGrath PJ, Berman SR.
    Drug Alcohol Depend; 2009 Jan 01; 99(1-3):248-60. PubMed ID: 18986774
    [Abstract] [Full Text] [Related]

  • 7. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T.
    Biol Psychiatry; 2006 Jun 01; 59(11):1052-60. PubMed ID: 16581036
    [Abstract] [Full Text] [Related]

  • 8. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
    Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U.
    J Neurol; 2003 Mar 01; 250(3):347-51. PubMed ID: 12638027
    [Abstract] [Full Text] [Related]

  • 9. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 10. Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline.
    Joyce PR, Mulder RT, McKenzie JM, Luty SE, Cloninger CR.
    Depress Anxiety; 2004 Oct 30; 19(3):180-6. PubMed ID: 15129420
    [Abstract] [Full Text] [Related]

  • 11. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
    Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.
    Psychiatry Clin Neurosci; 2011 Aug 30; 65(5):510-7. PubMed ID: 21851460
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
    Sandor P, Baker B, Irvine J, Dorian P, McKessok D, Mendlowitz S.
    Depress Anxiety; 1998 Aug 30; 7(2):69-72. PubMed ID: 9614594
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB, Thase ME, EPIC 014 Study Group.
    J Psychiatr Res; 2007 Aug 30; 41(3-4):351-9. PubMed ID: 16165158
    [Abstract] [Full Text] [Related]

  • 14. Fluoxetine versus placebo in depressed alcoholic cocaine abusers.
    Cornelius JR, Salloum IM, Thase ME, Haskett RF, Daley DC, Jones-Barlock A, Upsher C, Perel JM.
    Psychopharmacol Bull; 1998 Aug 30; 34(1):117-21. PubMed ID: 9564208
    [Abstract] [Full Text] [Related]

  • 15. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?
    Castrogiovanni P, Blardi P, De Lalla A, Dell'Erba A, Auteri A.
    Psychopharmacol Bull; 2003 Aug 30; 37(2):102-8. PubMed ID: 14566218
    [Abstract] [Full Text] [Related]

  • 16. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M.
    Ann Clin Psychiatry; 2007 Aug 30; 19(1):5-8. PubMed ID: 17453655
    [Abstract] [Full Text] [Related]

  • 17. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
    Nierenberg AA, Pava JA, Clancy K, Rosenbaum JF, Fava M.
    Biol Psychiatry; 1996 Oct 15; 40(8):691-6. PubMed ID: 8894060
    [Abstract] [Full Text] [Related]

  • 18. Problem-solving ability and comorbid personality disorders in depressed outpatients.
    Harley R, Petersen T, Scalia M, Papakostas GI, Farabaugh A, Fava M.
    Depress Anxiety; 2006 Oct 15; 23(8):496-501. PubMed ID: 16845662
    [Abstract] [Full Text] [Related]

  • 19. Treatment of depression in HIV-infected patients.
    Cazzullo CL, Bessone E, Bertrando P, Pedrazzoli L, Cusini M.
    J Psychiatry Neurosci; 1998 Nov 15; 23(5):293-7. PubMed ID: 9846034
    [Abstract] [Full Text] [Related]

  • 20. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.
    Wiethoff K, Bauer M, Baghai TC, Möller HJ, Fisher R, Hollinde D, Kiermeir J, Hauth I, Laux G, Cordes J, Brieger P, Kronmüller KT, Zeiler J, Adli M.
    J Clin Psychiatry; 2010 Aug 15; 71(8):1047-54. PubMed ID: 20673545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.